A randomized phase 2/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or …
H Mukae, H Yotsuyanagi, N Ohmagari… - Antimicrobial agents …, 2022 - Am Soc Microbiol
This multicenter, double-blind, phase 2a part of a phase 2/3 study assessed the efficacy and
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or …
H Mukae, H Yotsuyanagi, N Ohmagari, Y Doi… - 2022 - pesquisa.bvsalud.org
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease
Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 …
Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 …
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or …
H Mukae, H Yotsuyanagi, N Ohmagari… - Antimicrobial Agents …, 2022 - europepmc.org
This multicenter, double-blind, phase 2a part of a phase 2/3 study assessed the efficacy and
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or …
H Mukae, H Yotsuyanagi, N Ohmagari… - Antimicrobial agents …, 2022 - pure.fujita-hu.ac.jp
抄録 This multicenter, double-blind, phase 2a part of a phase 2/3 study assessed the efficacy
and safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS …
and safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS …
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or …
H Mukae, H Yotsuyanagi, N Ohmagari, Y Doi… - Antimicrobial Agents …, 2022 - cir.nii.ac.jp
抄録< jats: p> This multicenter, double-blind, phase 2a part of a phase 2/3 study assessed
the efficacy and safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus …
the efficacy and safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus …
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or …
H Mukae, H Yotsuyanagi… - Antimicrobial …, 2022 - pubmed.ncbi.nlm.nih.gov
This multicenter, double-blind, phase 2a part of a phase 2/3 study assessed the efficacy and
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
[HTML][HTML] A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or …
H Mukae, H Yotsuyanagi, N Ohmagari… - Antimicrobial Agents …, 2022 - ncbi.nlm.nih.gov
This multicenter, double-blind, phase 2a part of a phase 2/3 study assessed the efficacy and
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or …
H Mukae, H Yotsuyanagi, N Ohmagari, Y Doi… - medRxiv, 2022 - medrxiv.org
For the treatment of coronavirus disease 2019 (COVID-19), antiviral agents that can achieve
rapid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reduction are …
rapid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reduction are …
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or …
H Mukae, H Yotsuyanagi… - Antimicrobial …, 2022 - nagasaki-u.repo.nii.ac.jp
This multicenter, double-blind, phase 2a part of a phase 2/3 study assessed the efficacy and
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
[PDF][PDF] A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or …
H Mukae, H Yotsuyanagi, N Ohmagari, Y Doi… - 2022 - scienceopen.com
This multicenter, double-blind, phase 2a part of a phase 2/3 study assessed the efficacy and
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
safety of ensitrelvir, a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …